Previous Close | 0.3679 |
Open | 0.3600 |
Bid | 0.2520 x 200 |
Ask | 0.4550 x 200 |
Day's Range | 0.3499 - 0.3679 |
52 Week Range | 0.2800 - 18.4800 |
Volume | |
Avg. Volume | 280,195 |
Market Cap | 3.25M |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -16.7900 |
Earnings Date | Mar 29, 2024 - Apr 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.00 |
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the c
WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value. “We are pleased with the progress we have made in advancing our cardiovascular portfol
WARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with Windtree's ...